On Thursday, the Regen Biopharma Inc (OTCMKTS:RGBP) stock was a huge winner up much as 570% following a major development with regards to its pancreatic cancer treatment.
Today, the remarkable rally in the stock has continued as Regen Biopharma Inc (OTCMKTS:RGBP) shares trade higher. As of 12:45 RGBP were trading at .0247 up a whopping 75% adding .0107 so far in Fridays trading session. Volume was almost 1.3 Billion shares more than 5 times its 30 day average trading volume.
The company filed an 8k yesterday that it signed a licensing agreement with Oncology Pharma where they will get access to Regen Biopharma’s intellectual property. It goes without saying that it is a massive development for Regen, which is still a relatively small company.
On April 7, 2021 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property ( “License IP”) for the treatment in humans of pancreatic cancer for a term of fifteen years from April 7, 2021.
The License IP consists of antigen specific cancer vaccines in which modified mRNA is administered to produce epitopes able to produce an immune response which augments likelihood of successful induction of immunity. An epitope is the part of an antigen that is recognized by the immune system.
Potential pivot points to keep an eye on may be .0295, .033 and .046 if the stock continues to move higher.